Illumina and Nashville Biosciences announced that the Alliance for Genomic Discovery will grow to 312,000 whole‑genome sequences, a 20% increase over the 260,000‑sample baseline. The expansion adds the Regeneron Genetics Center as the consortium’s tenth member, bringing the total number of genomes in the dataset to 312,000.
The partnership also unveiled a new multi‑omics initiative that will add 50,000 whole‑genome samples paired with proteomic data generated with Illumina Protein Prep. GSK is among the first participants, underscoring commercial interest in integrated genomic‑proteomic datasets for drug discovery.
Illumina’s move fits into a broader multi‑omics strategy that includes the 2024 acquisition of SomaLogic, the launch of Illumina Protein Prep in September 2025, and the development of the Billion Cell Atlas. By combining genomics with proteomics, Illumina can offer a more comprehensive view of biological systems, creating new revenue streams and deepening its presence in precision medicine and pharmaceutical research.
The proteomics market is estimated at $5 billion, and Illumina’s expansion positions it to capture a larger share of that market. The addition of paired proteomic data to the AGD dataset strengthens Illumina’s competitive moat and provides partners with richer, multi‑layered data for target discovery and biomarker validation.
Financially, Illumina reported Q4 2025 revenue of $1.16 billion, up 5% year‑over‑year, and non‑GAAP diluted EPS of $1.35, beating analyst estimates. For fiscal 2026, the company guided total revenue of $4.5 billion to $4.6 billion, a 4%‑6% increase, and non‑GAAP diluted EPS of $5.05 to $5.20. Management highlighted strong demand in core segments and disciplined cost control as drivers of the positive outlook.
Analysts have maintained a hold rating on Illumina, citing the company’s solid financial performance and the strategic value of its multi‑omics expansion. The AGD and proteomics initiative is viewed as a key growth lever that complements Illumina’s existing sequencing business and positions the company for continued market leadership.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.